For the year ending 2025-12-31, NKTR has $280,406K in assets. $190,574K in debts. $15,116K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 15,116 | |||
| Short-term investments | 230,636 | |||
| Other current assets (including 429 and 0 as of december 31, 2025 and 2024, respectively, from a related party) | 20,514 | |||
| Total current assets | 266,266 | |||
| Long-term investments | 0 | |||
| Property, plant and equipment, net | 2,060 | |||
| Operating lease right-of-use assets | 2,941 | |||
| Equity method investment in gannet biochem | 3,491 | |||
| Other assets | 5,648 | |||
| Total assets | 280,406 | |||
| Accounts payable (including 137 and 0 as of december 31, 2025 and 2024, respectively, to a related party) | 10,770 | |||
| Accrued expenses (including 994 and 3,403 as of december 31, 2025 and 2024, respectively, to a related party) | 22,271 | |||
| Operating lease liabilities, current portion | 20,495 | |||
| Total current liabilities | 53,536 | |||
| Operating lease liabilities, less current portion | 65,256 | |||
| Liabilities related to the sales of future royalties ending balance | 63,971 | |||
| Less unamortized transaction costs | 814 | |||
| Liabilities related to the sales of future royalties, net | 63,157 | |||
| Other long-term liabilities | 8,625 | |||
| Total liabilities | 190,574 | |||
| Common stock, 0.0001 par value 390,000,000 shares and 300,000,000 shares authorized at december 31, 2025 and 2024, respectively 20,378,832 shares and 12,937,308 shares issued at december 31, 2025 and 2024, respectively 20,378,832 shares and 12,385,001 shares outstanding at december 31, 2025 and december 31, 2024, respectively | 2 | |||
| Capital in excess of par value | 3,850,099 | |||
| Accumulated other comprehensive income (loss) | 17 | |||
| Accumulated deficit | -3,760,286 | |||
| Total stockholders equity | 89,832 | |||
| Total liabilities and stockholders equity | 280,406 | |||
NEKTAR THERAPEUTICS (NKTR)
NEKTAR THERAPEUTICS (NKTR)